WP
CADL icon

Woodline Partners’s Candel Therapeutics CADL Stock Holding History

Woodline Partners’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-156,700
Closed -$768K – 1040
2026
Q1 		$768K Buy
+156,700
New +$853K ﹤0.01% 912
2022
Q1 		– Sell
-100,000
Closed -$782K – 736
2021
Q4 		$782K Hold
100,000
– – 0.01% 525
2021
Q3 		$1.08M Buy
+100,000
New +$829K 0.02% 502

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Woodline Partners's CADL Position: Q2 2026 in Review

Woodline Partners sold out of Candel Therapeutics (CADL) in Q2 2026, closing a stake of 156,700 shares — an estimated $768K sold.

Woodline Partners first reported a position in CADL in Q3 2021 and held it in 3 quarters. The position peaked at $1.08M in Q3 2021. 138 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

  • Woodline Partners reported no remaining Candel Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Woodline Partners sold 156,700 Candel Therapeutics shares in Q2 2026, an estimated $768K.
  • Woodline Partners first reported a position in Candel Therapeutics in Q3 2021 and held it in 3 quarters.
  • Woodline Partners's Candel Therapeutics position peaked at $1.08M in Q3 2021.
  • 138 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.